Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy. SVD can present as a stroke or cognitive decline, or can have few or no symptoms. SVD frequently coexists with neurodegenerative disease, and can exacerbate cognitive defi cits, physical disabilities, and other symptoms of neurodegeneration. Terminology and defi nitions for imaging the features of SVD vary widely, which is also true for protocols for image acquisition and image analysis. This lack of consistency hampers progress in identifying the contribution of SVD to the pathophysiology and clinical features of common neurodegenerative diseases. We are an international working group from the Centres of Excellence in Neurodegeneration. We completed a structured process to develop defi nitions and imaging standards for markers and consequences of SVD. We aimed to achieve the following: fi rst, to provide a common advisory about terms and defi nitions for features visible on MRI; second, to suggest minimum standards for image acquisition and analysis; third, to agree on standards for scientifi c reporting of changes related to SVD on neuroimaging; and fourth, to review emerging imaging methods for detection and quantifi cation of preclinical manifestations of SVD. Our fi ndings and recommendations apply to research studies, and can be used in the clinical setting to standardise image interpretation, acquisition, and reporting. This Position Paper summarises the main outcomes of this international eff ort to provide the STandards for ReportIng Vascular changes on nEuroimaging (STRIVE).
Introduction
Neurodegenerative diseases such as Alzheimer's disease commonly coexist with cerebrovascular disease in older people. Cerebral small vessel disease (SVD) is the most common vascular cause of dementia, a major contributor to mixed dementia, and the cause of about a fi fth of all strokes worldwide. 1, 2 Alzheimer's disease and SVD share risk factors 3, 4 and both lead to cognitive decline and dementia; [5] [6] [7] the clinical diff erentiation of Alzheimer's disease from vascular cognitive impairment or vascular dementia is increasingly recognised to be blurred. 8 Signs of SVD on conventional MRI include recent small subcortical infarcts, white matter magnetic resonance (MR) hyperintensities, lacunes, prominent perivascular spaces, cerebral microbleeds, and atrophy. 2 However, the terms for and defi nitions of these lesions have varied substantially between studies. 9, 10 For example, our systematic review identifi ed 1144 instances of 50 diff erent terms used to describe white matter hyperintensities in 940 papers; in some cases, two diff erent terms were used in the same paper (table 1; appendix). This amount of variation inhibits crossstudy comparisons and is a barrier to research on risk factors, pathophysiology, pathological correlations, and clinical consequences of these lesions. Indeed, the same lesions are classifi ed diff erently across studieseg, diff erent defi nitions have resulted in small cavities being classifi ed as perivascular spaces or lacunes. 9 Interpretation of data from many reports is hampered by the variable consequences of acute SVD and related lesions and the convergence of lesions with diff erent causes but similar late appearances on MRI (fi gure 1). Use of more standard terminology, defi nitions, and methods for image acquisition and analysis across research centres would remove a major barrier to progress. Furthermore, such standardisation could be used in clinical practice to improve diagnosis and better understand the cause of cognitive impairment in elderly patients.
Neuroimaging consensus standards for classifi cation of SVD were fi rst proposed by the US National Institute of Neurological Disorders and Stroke and the Canadian Stroke Network as part of the development of standards for research on vascular cognitive impairment. 11 Subsequently, a scientifi c statement from the American Heart Association incorporated neuroimaging evidence for SVD or stroke as part of the criteria for probable vascular mild cognitive impairment and dementia, and included a class 2 recommendation for neuroimaging as part of the clinical investigation of vascular cognitive impairment. 12 However, neither of these guidelines provide comprehensive recommendations for the many forms of SVD seen on neuroimaging, and neither include advances in understanding the pathophysiology and measurement of SVD, which are changing rapidly.
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Our international eff ort builds on previous initiatives and aims to provide clear, rigorous, evidence-based, and easy-to-apply defi nitions and terminology for the structural neuroimaging features of SVD that avoid presumption of mechanisms of pathogenesis. We include examples to help improve the standard use, minimum advisory standards for image acquisition, standards for analysis of imaging data on SVD and related features, and scientifi c reporting standards to improve clarity of publications on SVD.
Although this Position Paper focuses on the most common manifestations of SVD, other vascular lesions, such as ischaemic or haemorrhagic stroke, subarachnoid haemorrhage, subdural haematoma, and vascular malformations unrelated to SVD, can also contribute to cognitive impairment and dementia, especially after stroke. We provide a description of their features and neuroimaging recommendations in the appendix.
This Position Paper summarises the STandards for ReportIng Vascular changes on nEuroimaging (STRIVE). Our main aim is to recommend standards for research with MRI; however, many of the principles also apply to research with CT, and the standards might also facilitate a more consistent approach to identifi cation of manifestations of SVD on neuroimaging in clinical practice.
Methods
In 2011, the UK Medical Research Council (London, UK), the German Centre for Neurodegenerative Disease (DZNE, Bonn Germany), and the Canadian Institutes of Health Research (Ottawa, ON, Canada) issued a call for proposals under a funding concordat of the Centres of Excellence in Neurodegeneration (COEN), which aimed to accelerate progress in understanding the pathogenesis of neurodegeneration. 13 This initiative provided funding for a working group of experts to establish standards for neuroimaging in SVD.
In March, 2012, the core group of experts met in Edinburgh, UK. Three study co-chairs (JMW, MDi, and EES) identifi ed experts from COEN-affi liated centres and supplemented the group with representatives from research groups active in neuroimaging of SVD from non-COEN participant countries. Our group included experts in neurology, neuroradiology, neuro epidemiology, psychiatry, geriatrics, stroke, medical imaging physics, and neuropathology. The working method was based on the Delphi principle with workshops at the beginning and end of the project, and with interim work assignments (appendix). A template helped discussion to focus on achievement of a consensus in key areas: terminology, defi nitions, image acquisition, image analysis, and reporting standards. We endorsed the principle that terms and defi nitions should indicate imaging characteristics as descriptively as possible, avoiding presumptions of mechanism or pathological links not well supported by published reports so as to not aff ect future studies of the pathophysiology of SVD. Working groups developed standards for each of the six key lesion types, using established principles for guideline development published by the Enhancing the QUAlity and Transparency Of health Research (Equator) Network. We did systematic searches to identify relevant published work (appendix). The group reconvened in Munich, Germany, in November, 2012, to present draft standards from each working group for discussion and revision, with additional review and comment from six new external advisers. We wrote and revised the consensus document with input from all workshop members. All participants reviewed and endorsed the fi nal document.
For the defi nition of SVD, we discussed size limits to defi ne perforating arteries and arterioles, but they were highly variable in published work, and did not translate well to their appearance on imaging. Therefore, we decided to use the term arteriole to refer to small perforating arteries and arterioles that are aff ected in SVD. These standards are expected to reliably classify most manifestations of SVD seen on neuroimaging; however, we acknowledge that individual judgment might be needed for classifi cation of ambiguous lesions on the borders between categories (appendix), and that clinical judgment might be needed in some cases when using these standards in clinical practice.
Context, terminology, and defi nitions of imaging features

Recent small subcortical infarct Context
Clinically evident recent small subcortical infarcts, commonly called lacunar strokes or lacunar syndrome, cause about 25% of all ischaemic strokes (fi gure 2). Occasionally, a recent asymptomatic small subcortical infarct is identifi ed by chance on imaging, 14, 15 and is referred to as a silent cerebral infarct. By contrast, for as yet unknown reasons, in up to 30% of patients, symptomatic lacunar stroke syndromes seem not to be accompanied by visible small subcortical infarcts, 16 indicating that MRI is not fully sensitive in the detection of such infarcts. Additionally, some studies have shown that the small subcortical infarcts might have diff ering fates, evolving into a lacunar cavity or hyperintensity without apparent cavitation on T2-weighted sequences, or might disappear leaving little visible consequence on conventional MRI (fi gure 1). Estimates of the proportion of recent small subcortical infarcts that cavitate range from 28% 17 to 94%. Scarce data from pathological correlation studies suggest that small subcortical infarcts are associated with occlusion of small arteries, although the pathogenesis of these infarcts is unclear. Small subcortical infarcts occur in the perfusion territory of a small artery or arteriole penetrating the internal part of the brain. MRI studies suggest that recent small subcortical infarcts can exceed a diameter of 15 mm on axial sections (the usual size limit for lacunes of presumed vascular origin) in the acute phase, and can be up to about 20 mm on axial sections. MRI also shows that small subcortical infarcts and lacunes can be more than 20 mm long when measured in the coronal or sagittal plane (appendix).
Terminology
We sampled 641 abstracts and one previous systematic review 9 and identifi ed 159 diff erent terms for recent small subcortical infarcts; the most common terms were lacunar infarcts, lacunar infarctions, and lacunar strokes (appendix). We propose the new consensus term recent small subcortical infarct, removing the word lacunar because of evidence that not all small subcortical infarcts become lacunes (ie, cavities). 17, 18 
Defi nition
We propose that the term recent small subcortical infarct should refer to neuroimaging evidence of recent infarction in the territory of one perforating arteriole, with imaging features or clinical symptoms consistent with a lesion occurring in the previous few weeks (fi gure 2, panel 1). Use of the word recent should refer to lesions with symptoms or imaging features that suggest they occurred in the previous few weeks; the word is used instead of acute because it includes the fi rst few weeks of the lesion, and not the hyperacute stage only. Use of the word small indicates a lesion that should be less than 20 mm in its maximum diameter in the axial plane, although some lesions that appear to represent infarction in the territory of one vessel can be somewhat larger in the coronal plane (appendix). 19 More investigation is needed to precisely defi ne upper size limits.
Lesions in the basal ganglia and internal capsule that are larger than 20 mm and seem to be due to simultaneous infarction in several penetrating arteries should not be classifi ed as small subcortical infarcts, but rather as striatocapsular infarcts, a subtype of infarct with a distinct cause. 20 Similarly, infarcts of the anterior choroidal artery are aetiologically distinct, identifi able by their location (in the caudate nucleus head), and shape (mostly comma shaped), and therefore should not be classifi ed as small subcortical infarcts. Unlike lacunes of presumed vascular origin, no lower size limit is given for small subcortical infarcts because diff usion-weighted imaging allows discrimination of small recent infarcts from perivascular spaces.
Lacune of presumed vascular origin Context
Regarding pathological changes, Fisher 21 wrote: "Historically, the original SVD feature was the lacune (hole), which derived from French for a small fl uid-fi lled cavity that was thought to mark the healed stage of a small deep brain infarct. The term was adopted into English. By a process of medico-linguistic evolution, the precavitary phase became the lacunar infarct, the associated clinical entity became the lacunar stroke and the neurological features became the lacunar syndrome." Lacunes are frequently seen on imaging in elderly patients with no symptoms and are associated with an increased risk of stroke, gait impairment, and dementia. [22] [23] [24] [25] The cause of 
Lacune of presumed vascular origin
A round or ovoid, subcortical, fl uid-fi lled cavity (signal similar to CSF) of between 3 mm and about 15 mm in diameter, consistent with a previous acute small subcortical infarct or haemorrhage in the territory of one perforating arteriole.
White matter hyperintensity of presumed vascular origin
Signal abnormality of variable size in the white matter that shows the following characteristics: hyperintensity on T2-weighted images such as fl uid-attenuated inversion recovery, without cavitation (signal diff erent from CSF). Lesions in the subcortical grey matter or brainstem are not included in this category unless explicitly stated. If deep grey matter and brainstem hyperintensities are also included, the collective term should be subcortical hyperintensities.
Perivascular space
Fluid-fi lled spaces that follow the typical course of a vessel as it goes through grey or white matter. The spaces have signal intensity similar to CSF on all sequences (fi gure 2). Because they follow the course of penetrating vessels, they appear linear when imaged parallel to the course of the vessel, and round or ovoid, with a diameter generally smaller than 3 mm, when imaged perpendicular to the course of the vessel.
Cerebral microbleed
Small (generally 2-5 mm in diameter, but sometimes up to 10 mm) areas of signal void with associated blooming seen on T2*-weighted MRI or other sequences that are sensitive to susceptibility eff ects.
Brain atrophy
A lower brain volume that is not related to a specifi c macroscopic focal injury such as trauma or infarction. Thus, infarction is not included in this measure unless explicitly stated.
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most lacunes is presumed to be small subcortical infarcts, either symptomatic or silent; however, some might result from small deep haemorrhages (fi gure 1). 26 
Terminology
Our systematic review identifi ed more than 100 terms that have been used to describe lacunes of presumed vascular origin (appendix). Commonly used terms were lacune, lacunar stroke, and silent brain infarct. We propose the new term lacune of presumed vascular origin, which discriminates between small cavitated lesions of presumed vascular origin and other small brain cavities, and allows for some uncertainty about the ischaemic or haemorrhagic origin of the lesion when no imaging is available in the acute phase, as is commonly the case (panel 1).
Defi nitions
We defi ne a lacune of presumed vascular origin as a round or ovoid, subcortical, fl uid-fi lled (similar signal as CSF) cavity, of between 3 mm and about 15 mm in diameter, consistent with a previous acute small deep brain infarct or haemorrhage in the territory of one perforating arteriole (panel 1). On fl uid-attenuated inversion recovery (FLAIR) images, lacunes of presumed vascular origin generally have a central CSF-like hypointensity with a surrounding rim of hyperintensity; however, the rim is not always present, and a hyperintense rim can also surround perivascular spaces when they pass through an area of white matter hyperintensity (fi gure 2). In some cases, the central cavity fl uid is not suppressed on FLAIR, and the lesion can appear entirely hyperintense, despite MRI having a clear CSF-like intensity on other sequences such as T1-weighted and T2-weighted MRI. 18 Lacunes of presumed vascular origin should be distinguished from perivascular spaces. Although pathological studies have not shown an absolute cutoff size, lesions that are less than 3 mm in diameter are more likely to be perivascular spaces than to be lacunes (appendix), and we recommend the use of this size criterion to discriminate between the two lesions, which is consistent with previous studies. 27, 28 We chose a maximum size of 15 mm for lacunes of presumed vascular origin-which diff ers from the 20 mm diameter of recent small subcortical infarcts-since old infarcts are generally smaller than recent infarcts because of tissue loss and an ex-vacuo eff ect in old lesions, and because of swelling in new lesions. However, we recognise that this size boundary is not supported by much objective evidence, and research is needed.
White matter hyperintensity of presumed vascular origin Context
White matter lesions characterised by bilateral, mostly symmetrical hyperintensities on T2-weighted MRI are common in older individuals. Although strongly associated with cerebrovascular disease and vascular risk factors, 29 the pathogenesis of these white matter lesions is not well understood and could be multifactorial. 30 White matter hyperintensities are associated with covert neurological and cognitive symptoms and physical diffi culties such as gait disturbance. [31] [32] [33] [34] [35] Hyperintensities can also occur in subcortical grey matter structures, such as the basal ganglia, and have sometimes been analysed alongside white matter hyperintensities. Hyperintensities can also be present in the brainstem. Some investigators have diff erentiated between hyperintensities of periventricular and deep white matter (appendix), with the suggestion, under debate, that they have diff ering pathogenesis, risk factors, and clinical consequences. Many investigators have included total white matter hyperintensities in their analyses.
Terminology
Our systematic review of 940 abstracts identifi ed 50 diff erent terms for white matter hyper intensity. The most common terms were leukoaraiosis, white matter lesions, white matter hyperintensities, leuko encephalopathy (usually in the context of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]), and white matter disease (table 1; appendix).
Leukoaraiosis describes a reduced area of x-ray attenuation on CT, 36 and this term was later adopted to denote hyperintensity on T2-weighted and FLAIR MRI, and sometimes also hypointensity on T1-weighted MRI (appendix), a situation in which the radiological description came before the pathological description. We propose the term white matter hyperintensity of presumed vascular origin to exclude white matter lesions from other diseases such as multiple sclerosis or leukodystrophies.
Defi nitions
White matter hyperintensities of presumed vascular origin are hyperintense on T2-weighted sequences and can appear as isointense or hypointense (although not as hypointense as CSF) on T1-weighted sequences, depending on the sequence parameters and severity of pathological change (fi gure 2, panel 1; appendix). Members of our group had diff ering opinions about whether grey matter hyperintensities or brainstem hyperintensities should be routinely classifi ed as white matter hyperintensities, as some previous studies have done. The consensus opinion was that lesions in the subcortical grey matter or brainstem should not be included in the category of white matter hyperintensity of presumed vascular origin unless explicitly stated; we endorsed subcortical hyperintensities as an acceptable alternative collective term for any non-cortical hyperintensities, including those in white matter, deep grey matter, and the brainstem. When using CT, white matter hypoattenuation or white matter hypodensities can be used because of the appearance of the lesions on CT.
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Perivascular space Context
Perivascular spaces are extensions of the extracerebral fl uid space around arteries, arterioles, veins, and venules as they course from the brain surface into and through the brain parenchyma, and they can be followed by sheets of leptomeninges. 37 Perivascular spaces are commonly microscopic, and not visible on conventional neuroimaging; however, larger spaces become increasingly apparent with increasing patient age, especially when located at the base of the brain. 38 General enlargement of perivascular spaces is associated with other morphological features of SVD such as white matter hyperintensities 39 and lacunes, 40 but not atrophy. 41 Whether the presence of several visible perivascular spaces is clinically signifi cant remains controversial, and the spaces should therefore not be referred to as lesions; however, some studies have associated more prominent perivascular spaces with worse cognitive function. 42 
Terminology
Synonymous terms for perivascular spaces include Virchow-Robin spaces, 40 type 3 lacune, 43 or état crible when located predominantly in the basal ganglia. 38 Terms used to describe visible perivascular spaces include large, dilated, large dilated, or enlarged Virchow-Robin spaces or perivascular spaces. 38, 41, 42, [44] [45] [46] [47] [48] We did not consider these terms appropriate because the association between the size of the perivascular spaces and clinical consequences is not well understood, and because the visibility of the spaces depends on MRI sequence characteristics, which vary across studies. Visibility alone cannot be a uniform criterion for pathologically enlarged perivascular spaces. We therefore recommend the consensus term perivascular space.
Defi nitions
We defi ne perivascular spaces as fl uid-fi lled spaces that follow the typical course of a vessel as it goes through grey or white matter. The spaces have signal intensity similar to that of CSF on all sequences (fi gure 2); because they follow the course of penetrating vessels, they appear linear when imaged parallel to the course of the vessel, and round or ovoid, with a diameter generally smaller than 3 mm, when imaged perpendicular to the course of the vessel (panel 1, appendix). At high resolution, a central vessel can occasionally be seen in the centre of a perivascular space, which could possibly diff erentiate the spaces from lacunes. Perivascular spaces are generally most prominent in the inferior basal ganglia, and can also be seen coursing centripetally through the hemispheric white matter and in the midbrain; however, the spaces are rarely seen in the cerebellum. Perivascular spaces can show focal enlargement, and can be especially enlarged (up to 10-20 mm, even with mass eff ect) in the inferior basal ganglia. Perivascular spaces must be discriminated from small lacunes of presumed vascular origin (appendix). By contrast with lacunes, the diameter of perivascular spaces is not usually more than 3 mm as confi rmed pathologically, 49, 50 and spaces do not have a T2-hyperintense rim around the fl uid-fi lled space on T2-weighted or FLAIR imaging, unless they traverse an area of white matter hyperintensity. 51 
Cerebral microbleed Context
Cerebral microbleeds are small hypointense lesions that are visible on paramagnetic-sensitive MR sequences such as T2*-weighted gradient-recalled echo (GRE) or susceptibility-weighted sequences, and are most commonly located in the cortico-subcortical junction, and deep grey or white matter in the cerebral hemispheres, brainstem, and cerebellum (fi gure 2). Results of some studies 30, 52, 53 suggest that MR-visible lesions correspond to haemosiderin-laden macrophages in perivascular tissue, consistent with vascular leakage of blood cells. 52, [54] [55] [56] Cerebral microbleeds are associated with SVD and Alzheimer's disease. 57, 58 The presence or absence of strictly lobar microbleeds has been included in research criteria for cerebral amyloid angiopathy. 59 Originally thought to be asymptomatic markers of SVD, emerging data shows association between microbleeds and cognitive impairment, although the mechanisms of this association, including whether microbleeds damage the brain and cause dysfunction, are not well understood. Recommendations for imaging and reporting of microbleeds have been published, 60 and we endorse the use of these standards. Amyloid-related imaging abnormalities-haemorrhage (ARIA-H) describes microbleeds in the context of Alzheimer's disease or β-amyloid immunotherapies. A consensus group from the US Alzheimer's Association has published standards for assessing microbleeds in this specifi c clinical context, 61 and we also endorse the use of these guidelines.
Terminology
Our systematic review revealed 387 instances of 20 diff erent terms for microbleeds in 370 abstracts (appendix). Microbleed was by far the most common term, followed by cerebral microbleed, then brain microbleed. We propose the consensus term cerebral microbleed.
Defi nitions
Cerebral microbleeds are visualised as small (generally 2-5 mm in diameter, but up to 10 mm) areas of signal void with associated blooming seen on T2*-weighted MRI or other sequences that are sensitive to susceptibility eff ects (panel 1), 57, 60 and are generally not seen on CT, or on FLAIR, T1-weighted, or T2-weighted sequences. When imaged with T2*-weighted GRE sequences, cerebral microbleeds are well defi ned, of homogeneous low signal, and are either round or oval in shape (fi gure 2). Because the blooming artifact, and therefore the visualised size, Position Paper depends on MR fi eld strength and sequence, we do not recommend an absolute criterion for size. When imaged with 1·5 T and 3·0 T GRE sequences, cerebral microbleeds are generally 2-5 mm in diameter, but can be up to 10 mm. Hypointensities of less than 2 mm, which could be attributable to signal loss from only one voxel, should be regarded as questionable on 1·5 T MRI because such small hypointensities could be artifacts.
Susceptibility-weighted imaging can also be used to assess cerebral microbleeds. New quantitative-based methods (ie, quantitative susceptibility mapping) need more investigation, but might improve the assessment of cerebral microbleeds. Several lesions or structures can mimic cerebral microbleeds, such as calcifi cation, normal vessels seen in cross-section, iron deposits from other causes, haemorrhagic metastases (eg, melanoma), and diff use axonal injury (eg, after head trauma). 60 Cerebral microbleeds can be diff erentiated from an old small deep spontaneous intracerebral haemorrhage because, in general, the intracerebral haemorrhages are larger, irregular with a cystic cavity (fi gure 1), and will be visible on T1-weighted and T2-weighted or FLAIR sequences.
Other haemorrhagic lesions
We discussed two other haemorrhagic manifestations of SVD: intracerebral haemorrhage and superfi cial cortical siderosis (appendix). Intracerebral haemorrhage could be a manifestation of SVD 62 or secondary to other causes such as vascular malformations. We suggest the use of the consensus term spontaneous intracerebral haemorrhage presumed to be due to SVD, instead of secondary intracerebral haemorrhage from other causes or traumatic intracerebral haemorrhage. Comprehensive guidelines for the diagnosis and management of intracerebral haemorrhage have been published previously. 63 In the context of SVD, we encourage researchers to resolve the contribution of diff erent vascular diseases to intracerebral haemorrhage. In the meantime, we recommend that lobar intracerebral haemorrhages, which might be caused by cerebral amyloid angiopathy, should be distinguished from nonlobar intracerebral haemorrhages, which are not thought to be caused by cerebral amyloid angiopathy, and are mostly due to perforating arteriolar vasculopathy. 64, 65 Results of a small study 66 suggested good, but not perfect, inter-rater agreement on the site of origin of intracerebral haemorrhages. The Boston criteria 59 for cerebral amyloid angiopathy should be used in assigning the likelihood of underlying cerebral amyloid angiopathy in patients with lobar intracerebral haemorrhages.
We propose the term superfi cial cortical siderosis for neuroimaging evidence of chronic blood products in the superfi cial cortex under the pia mater. Superfi cial cortical siderosis could be a chronic consequence of subarachnoid bleeding or might be the result of very superfi cial cortical bleeding caused by vascular malformations, cerebral amyloid angiopathy, 67 spinal dural defects, or it might also be idiopathic. 67, 68 T2*-weighted GRE or other blood-sensitive sequences will show superfi cial cortical siderosis as a linear hypointensity over the cortex, but this disorder might be mimicked by the petechial cortical haemorrhagic transformation of an infarct. Revised research criteria for cerebral amyloid angiopathy include superfi cial cortical siderosis as an additional haemorrhagic manifestation of cerebral amyloid angiopathy, equivalent to a lobar intracerebral haemorrhage. 67 Investigators should describe the location of siderosis (ie, the number of sulci involved 67 and in which lobes).
Brain atrophy Context
Brain atrophy can be general or focal (aff ecting only particular lobes or specifi c brain regions-eg, the hippocampus), symmetrical or asymmetrical, or tissue selective (aff ecting a certain tissue class-eg, white matter), and occurs in many disorders. The pathological changes of atrophy are heterogeneous and not necessarily indicative of neuronal loss. [69] [70] [71] Brain atrophy occurs with the usual ageing process, but the extent varies between individuals. In the context of vascular disease and dementia, neuropathological substrates of atrophy include neuronal loss, 72 cortical thinning, subcortical vascular pathology with white matter rarefaction and shrinkage, arteriolosclerosis, venous collagenosis, and secondary neurodegenerative changes. 73, 74 Many imaging studies report an association between the presence and severity of SVD and brain atrophy, including global atrophy, corpus callosum atrophy, central atrophy (increased ventricular size and atrophy of the basal ganglia), mesencephalic atrophy, and hippocampal atrophy, and focal cortical thinning in brain regions connected to subcortical infarcts (fi gure 3). 75, 76 Therefore, vascular lesions should be included in studies of atrophy; conversely, atrophy is an important measure in imaging studies that are done to 
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assess the burden of vascular damage in the brain, and atrophy is thought to mediate, at least partially, the eff ects of vascular lesions on cognition.
77-79
Terminology
Our systematic review of studies on SVD and atrophy revealed the use of many synonymous terms, including atrophy, brain volume, volume loss, and others. We propose the consensus term brain atrophy. We also propose that studies should use unambiguous terms about whether the atrophy assessment was crosssectional or longitudinal, and should avoid terms such as accelerated atrophy or brain volume loss in crosssectional studies in favour of more atrophy or lower brain volume, respectively. When discussing atrophy, investigators should be clear about the specifi c brain volumes they have measured and should include the brain subregion in their description-eg, hippocampal atrophy.
Defi nitions
We defi ne brain atrophy in the context of SVD on imaging as a lower brain volume that is not related to a specifi c macroscopic focal injury such as trauma or infarction (panel 1). Tissue loss is assumed from the enlargement of peripheral (sulcal) and central (ventricular) CSF spaces in relation to intracranial volume and other measures (fi gure 3). However, ideally, such assumptions should be formally confi rmed with longitudinal observation. Tissue loss from discrete focal lesions, such as cortical infarcts, is easier to see on cross-sectional imaging, and should not be confused with generalised global or regional brain atrophy that is probably secondary to a diff use process.
Other vascular lesions
These consensus standards focus on SVD. However, other vascular lesions can also be seen on imaging, particularly in elderly individuals and in those with cognitive impairment. These include ischaemic lesions unrelated to SVD, intracerebral haemorrhage from other causes, subarachnoid haemorrhage, subdural haematoma, vascular malformations, and large artery ischaemic disease. These features are discussed in detail in the appendix.
Advised minimum standards and parameters for imaging of SVD Image acquisition
If no contraindications are known, MRI, rather than CT, is preferred for research and routine clinical use because it has higher sensitivity and specifi city for detecting most manifestations of SVD (table 2) . A fi eld strength of 3·0 T might be preferred, but images from modern 1·5 T MRI scanners are often of a similarly high defi nition, 80 and are therefore acceptable; 1·5 T systems are also more widely available than 3·0 T systems, an important consideration for multicentre studies. Imaging sequences should be optimised for fi eld strength and scanner confi guration. If CT is used to image SVD, investigators should obtain a thin-section volume sequence, without contrast, covering the whole brain, and using a brain parenchymal algorithm and axial 5 mm reconstructions. However, CT is no longer recommended, except possibly in large-scale epidemiological studies, or if MRI is not available or is too expensive.
For MRI, the minimum acceptable examination should include axial diff usion-weighted imaging (and apparent diff usion coeffi cient map), FLAIR, T2-weighted, and T2*-weighted GRE or susceptibilityweighted imaging, and T1-weighted imaging. The diff usion-weighted imaging sequence is very important for identifi cation of recent infarcts-eg, when used in patients with symptoms. MRI with diff usion-weighted imaging should be considered the reference standard for recent small subcortical infarcts, although results might be falsely negative in some cases. 16 The combination of clinical syndrome plus MRI results but without diff usion-weighted imaging, or clinical syndrome plus CT results, is not optimal; clinical The use of one sequence (usually T1-weighted MRI) in the coronal or sagittal plane instead of the axial plane helps to visualise the correct lesion dimensions (appendix). Slice thickness should be 5 mm or less, ideally with no gap; in-plane resolution should be 1 mm by 1 mm or better. Whole-brain coverage is recommended for all sequences to achieve optimum image analysis. Three-dimensional T1-weighted thin-section isotropic sequences are now widely available and quick and can be reformatted on thicker slices for ease of viewing in multiple planes; this sequence also allows anatomical coregistration and quantifi cation of brain volume. The Alzheimer's Disease Neuroimaging Initiative has validated threedimensional magnetisation prepared T1-weighted sequence protocols for the major scanner types at 1·5 T and 3·0 T; sequence protocols are freely available.
For a comprehensive research MRI protocol for SVD, investigators should consider use of higher-resolution MRI than the sequences specifi ed above, and use volume acquisitions to allow for volumetric whole-brain imaging with near-isotropic resolution. These three-dimensional acquisitions are now possible on most scanners for 
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T1-weighted, T2-weighted, GRE, and FLAIR techniques.
Other high-resolution sequences sensitive to paramagnetic content, such as susceptibility-weighted imaging and equivalents, should be considered for three-dimensional image acquisition, although these sequences increase the presence of artifacts. Diff usion tensor imaging builds on fi ndings with diff usion-weighted imaging, and should be used in research protocols. Diff usion tensor imaging is useful in the assessment of surrogates for microarchitectural integrity in normal-appearing and lesional white matter, in the determination of structural connectivity of white matter, and in tractography. For quantitative volumetric assessments of atrophy, we advise a high-resolution (1·0 mm to 1·5 mm isotropic voxels) T1-weighted sequence with good grey-white matter diff erentiation. Other MR measurements show promise for imaging of SVD in research, including measurements of perfusion, magnetisation transfer, blood-brain barrier permeability, vascular reactivity, metabolites, and microatheroma in perforating arterioles.
Image analysis
Qualitative (visual rating) and quantitative (computational analysis) methods are established or are emerging for all lesion types. For some of the lesions, qualitative and quantitative approaches are closely related, 82, 83 and both have advantages and disadvantages that should be considered in the design of any study of SVD (appendix).
For all lesion types, observers should be trained in neuroimaging interpretation, and specifi cally how to recognise lesions of SVD. If possible, particularly in trials or large observational studies, images should be rated centrally by one or a few experienced raters. In studies with more than one rater, inter-rater reliability should be assessed. Observers should have good knowledge of normal neuroanatomy to measure global and regional atrophy. Observers should train on established training sets, and should aim for high observer agreement before taking actual measure ments. Regular recalibration against standard examples is useful to maintain consistency when rating large numbers of scans or when rating images from diff erent sessions.
When investigators use automated computational methods for analysis, we emphasise that the accuracy of each individual's results should be visually confi rmed by a trained observer. This validation step is crucial for studies of SVD because automated methods have not been developed for the disorder, and there is a high risk of misclassifi cation of lesions, especially when unfamiliar pulse sequences are used or scanners are upgraded. Known examples to avoid are the misclassifi cation of white matter hyperintensities as normal grey matter, of lacunes as ventricle or white matter hyperintensity, or of small subcortical infarcts as white matter hyperintensities. 84 For several of these misclassifi cations, manual correction will be needed. 78, 85 For small numbers of discrete lesions, such as recent small subcortical infarcts, lacunes, and microbleeds, we recommend that the location of each lesion and the total number of lesions are recorded. At minimum, we recommend recording of the number of lesions in each of the following brain subregions, on both the right and left sides: cerebral cortex (divided by lobe), corona radiata and centrum semiovale, putamen, globus pallidus, thalamus, internal capsule, external capsule, brainstem, and cerebellum ( DWI=diff usion-weighted imaging. 
Image acquisition
• Scanner characteristics (type and manufacturer, fi eld strength, coils, high-order shim and use of shimming routines, quality assurance protocol for scanner and frequency of quality assurance assessment).
• Use of several scanners.
• Change of scanners or change to scanner system during study.
• MRI sequences, acquisition parameters (including as appropriate: repetition time, echo time, inversion time, echo train length), acquisition and reconstruction matrices, fi eld-of-view, slice thickness including gaps and scanning plane, details of selected options (tailored excitation pulses, parallel imaging, fl ow compensation, preparation pulses, etc), and total acquisition time. If a work-in-progress package is used, provide as much information as possible.
Image analysis and postprocessing
• Use and qualifi cation of a central analysis facility, or training procedure across several analysis centres.
• Whether analyses were done blinded to initial presentation or to other data (should be specifi ed) that might aff ect interpretation.
• Details of qualitative visual rating and quantitative computational methods, including the URL if available for download or an appendix describing the method in detail.
• For visual rating scales: whether images were rated centrally by one or a small number of readers; the raters' background (eg, neurology, psychiatry, neuroradiology, or radiology) and experience; rater reliability (intra-rater and inter-rater).
• For studies using computational image analysis programmes: training of the analysts, any expert supervision, and the background of the expert; repeatability.
• Statistical methods used in data analysis.
• Ideally: sample size estimation.
Small vessel disease-specifi c aspects
• For recent small subcortical infarcts: specify whether infarcts are symptomatic or not; state the location, size, shape, and number; specify the delay from stroke to imaging; state the proportion with visible acute lesion on diff usion-weighted imaging and fl uid-attenuated inversion recovery, plus T2-weighted imaging.
• For lacunes of presumed vascular origin: specify location, size, shape, and number; distinguish haemorrhagic lesions from lacunes; for volumetric methods, state whether lacunes are counted as part of CSF volume, as part of the white matter hyperintensity volume, or as separate lacune volume.
• For white matter hyperintensities of presumed vascular origin: specify whether deep grey matter and brainstem hyperintensities are included (and if so, refer to all hyperintensities collectively); state the rating scale or volume measurement software used and observer reliability; specify whether the white matter hyperintensity volume was adjusted for intracranial or brain volume and how this was done; state whether lacunes were included in white matter hyperintensities or measured separately and whether acute lesions were masked. • For perivascular spaces: separate perivascular spaces of the basal ganglia and white matter; describe how qualitative aspects (number, location, size, etc) are defi ned; state the observer reliability of the rating scale.
• For cerebral microbleeds: specify number and distribution divided into lobar, deep, and infratentorial (brainstem and cerebellum); provide full details of image acquisition parameters; specify application of standardised rating scales. • For atrophy: specify the rating scale or method of volume measurement, whether corrected for intracranial volume, and method used to do this. 
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are advances in small-artery imaging with ultra-high-fi eld strength MRI (>3·0 T), diff usion tensor imaging of detailed structural connectivity, magnetisation transfer assessment of white matter myelination, imaging of blood-brain barrier permeability and of vascular reactivity, perfusion imaging, imaging of retinal vessels, quantitative susceptibility imaging, and others. The advantages of multimodal imaging should be used to advance understanding of pathophysiology. For example, combining diff usion tensor imaging and atrophy allows the study of the eff ects of vascular lesions on distantly connected brain regions. 108 Interest is increasing in the clinical relevance of microinfarcts, another small infarct subtype. Microinfarcts are very small ischaemic lesions recorded mostly in the cortex during autopsy in older people, but are occasionally seen on high-fi eld MRI. 109, 110 Their true vascular pathological relation to SVD is still unknown. Although yet to be confi rmed, some very small cortical acute lesions seen on diff usion-weighted imaging might actually be microinfarcts. 109 Microinfarcts seem very clinically relevant, so neuroimaging methods to measure them or a validated close surrogate are needed. Larger cortical microinfarcts have been visualised on 7·0 T MRI, and these lesions were sometimes visible on conventional 3·0 T MRI. 111 We now need comprehensive studies that account for both vascular and neurodegenerative pathological changes in patients observed for longer and from a younger age than have been done so far (panel 3). These studies should incorporate some of the following: multimodal MRI, amyloid imaging with PET, detailed clinical testing, and biomarkers from serum and CSF to elucidate the crosstalk between vascular and neurodegenerative pathological changes, and how these interact to cause clinical symptoms, particularly cognitive decline, gait impairment, physical disability, and depression. Researchers should also investigate the connection between imaging and pathological changes. 30, 52 Additionally, carefully conducted imaging studies with short-term (eg, monthly) observational periods are needed to study the progression of imaging features of SVD and their eff ects on brain tissue loss.
Conclusions
Our neuroimaging standards for SVD are intended to harmonise current disparate terminology and analysis methods. We encourage other researchers to use these standards. They could provide a useful introduction to the principles of neuroimaging in SVD, which could help investigators to incorporate measurement of SVD into studies of neurodegenerative diseases or the pathological basis of ageing. These standards should allow cross-study comparisons of fi ndings, accelerating the translation of new fi ndings into practice. Additionally, standardised approaches could enable formal between-study metaanalyses, which are increasingly needed to obtain the sample sizes necessary for some types of research such as genetic association studies. We suggest that our reporting standards could be a useful guide to authors, peer reviewers, and editors, and might raise the methodological quality of neuroimaging studies of SVD as have analogous reporting standards (eg, the CONSORT guidelines) increased the quality of other types of research. Finally, although the primary purpose of our standards was for research, we hope that these standards will have a positive eff ect on clinical diagnosis and the reporting of SVD lesions in routine clinical practice.
These standards were developed on the basis of consensus in a large group of experts using rigorous methods. However, we acknowledge that in some parts of this rapidly evolving specialty, our recommendations are based on small studies, unvalidated fi ndings, or expert opinion without a strong body of supporting evidence. More work is essential to validate these standards. In particular, the lack of radiologicalpathological association studies is a key limitation to our understanding of the neuroimaging fi ndings in SVD. Additionally, best standards for neuroimaging of SVD will change over time and, therefore, periodic revision of these standards will be needed.
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